Coca-Cola is a publicly traded company in the Consumer sector. This company's performance is influenced by Congressional trade policy, tariff decisions, consumer protection regulations, and tax legislation affecting discretionary spending. HillSignal is tracking 9 active Congressional signals mentioning Coca-Cola, including 9 bills. The current legislative sentiment leans bearish, with regulatory or policy headwinds potentially affecting performance.
Coca-Cola ($KO) is currently facing 9 active congressional signals tracked by HillSignal. With 3 bullish, 2 neutral, and 4 bearish signals, covering 6 sectors. Key sectors affected include Consumer, Manufacturing and Agriculture. Recent major catalysts include Growing and Preserving Innovation in America Act of 2025 and No Tax Breaks for Outsourcing Act. Below is the complete tracker of government activity affecting Coca-Cola’s market performance.
9
Total Signals
Monitored
Action Status
3
Bullish Signals
4
Bearish Signals
HR 7807 is an early-stage procedural bill authorizing a claims commission for U.S. persons with expropriated property in Honduras. It allocates no funding and has no market impact on any publicly traded company. Recent moves in $KO, $PEP, $ADM, $XOM, $CVX are driven by earnings and commodity prices, not this legislation.
The Dietary Guidelines Reform Act of 2025 (HR2326) extends the federal dietary guideline update cycle from 5 to 10 years, providing direct regulatory relief to large packaged food and beverage manufacturers by halving mandatory reformulation frequency. The bill is early-stage (referred to subcommittee) with bipartisan cosponsors and an identical Senate companion, indicating moderate passage potential. Real market data shows consumer staples stocks have rallied 0.43% to 6.51% over the past 7 days, with $MDLZ leading at +6.51%.
HR7502 proposes a federal standard prohibiting misleading recycled content claims in consumer product marketing. The bill is in early committee stage with 9 cosponsors and limited legislative momentum. For $PG, $KO, $PEP, $KMB, and $CL, the bill imposes added compliance costs with no revenue offset — structurally bearish but low probability of passage in current form.
HR933 proposes reducing the FDA standard for orange juice soluble solids from 10.5% to 10.0%, a direct regulatory cost savings for major OJ producers. The bill is early-stage but has strong bipartisan Florida delegation support with 25 cosponsors. $KO, $PEP, and $KDP are the primary beneficiaries, with recent price trends showing a broad market recovery rather than bill-specific movement.
The No Tax Breaks for Outsourcing Act (S409) would eliminate tax deferral on foreign profits for U.S. multinationals, increasing effective tax rates by 5-8 percentage points. The bill is in early stages (referred to Senate Finance Committee, 19 cosponsors) and poses a 4-8% annual net income headwind for high international-exposure companies. Despite 8-30% rallies in the last 30 days across MSFT, AAPL, GOOGL, KO, PG, XOM, and CVX, this legislative risk is not currently priced into valuations.
HR1062 permanently locks in higher FDII and GILTI deductions for US multinationals, preventing a ~3.3 ppt effective tax rate increase on foreign IP income scheduled for 2026. This directly boosts after-tax net income for companies with large international revenue streams, including MSFT, AAPL, GOOGL, AMZN, NVDA, JNJ, PFE, KO, and PG. The bill is in early committee stage — structural impact is contingent on passage through the 119th Congress.
The PACK Act (HR6832) introduces new regulatory burdens for consumer packaged goods manufacturers by establishing strict requirements for recyclable, compostable, and reusable claims on product packaging. This bill, currently in the early stages of the legislative process, creates compliance costs for companies like Procter & Gamble, Coca-Cola, and PepsiCo. Recent market data shows mixed performance for these companies, with some experiencing gains and others declines over the past 7 and 30 days.
HR7945, the Nitrous Oxide Safety Act of 2026, is an early-stage bill referred to the House Energy and Commerce Committee. It would ban consumer products containing nitrous oxide but carves out broad exemptions for medical/dental use, commercial food production, and food products using N2O as a propellant — meaning no impact on major food/beverage companies. The bill has only one sponsor (a junior member) and one cosponsor, with no further legislative action since introduction. Market data shows no bill-related price movements.
The Childhood Diabetes Reduction Act (HR6294) mandates front-of-package health warning labels on sugar-sweetened beverages and ultra-processed foods, with labeling requirements on 5% of principal display area. Based on proven international precedent, this will cause 8-15% volume declines for targeted beverages and 4-8% for ultra-processed foods. The bill sits in early committee stage with a single Democratic sponsor and two cosponsors, presenting minimal near-term passage risk but creating a material regulatory overhang for $KO, $PEP, $MDLZ, and $KHC.
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →